Cochrane · systematic review · CD012378
Inositol for subfertile women with polycystic ovary syndrome
Showell, MG, Mackenzie‐Proctor, R, Jordan, V, et al. · Cochrane Database of Systematic Reviews · 2018 · Cochrane Library
Gynaecology and FertilityAMSTAR 2: not assessed
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
24
current version
GRADE rated
14
No studies
10
Included studies
NR
No studies 10 · 41.7%Ungraded 0 · 0%Very low 13 · 54.2%Low 1 · 4.2%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Myo‐inositol compared to placebo, no/standard treatment as pre‐treatment to IVF in women with PCOS
Population: subfertile women with polycystic ovary syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Live birth Myo‐inositol vs placebo, no/standard treatment | OR 2.42 [0.75, 7.83] | 2 studies · 84 participants | Very low Downgraded: risk of bias, imprecision |
Adverse event ‐ miscarriage Myo‐inositol vs placebo, no/standard treatment | OR 0.4 [0.19, 0.86] | 4 studies · 535 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Adverse event ‐ multiple pregnancy Myo‐inositol vs placebo, no/standard treatment | OR 1.04 [0.63, 1.71] | 2 studies · 425 participants | Low Downgraded: risk of bias, imprecision, inconsistency |
Clinical pregnancy Myo‐inositol vs placebo, no/standard treatment | OR 1.27 [0.87, 1.85] | 4 studies · 535 participants | Very low Downgraded: risk of bias, imprecision, inconsistency |
Ovulation Myo‐inositol vs placebo, no/standard treatment | no estimate extracted | NR | No studies |
Myo‐inositol compared to antioxidant (melatonin) as pre‐treatment to IVF in women with PCOS
Population: subfertile women with polycystic ovary syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Live birth Myo‐inositol vs antioxidant (melatonin) | no estimate extracted | NR | No studies |
Adverse event ‐ miscarriage Myo‐inositol vs antioxidant (melatonin) | OR 0.7 [0.22, 2.24] | 1 study · 358 participants | Very low Downgraded: risk of bias |
Adverse event ‐ multiple pregnancy Myo‐inositol vs antioxidant (melatonin) | OR 0.95 [0.57, 1.59] | 1 study · 358 participants | Very low Downgraded: risk of bias |
Clinical pregnancy Myo‐inositol vs antioxidant (melatonin) | OR 0.83 [0.53, 1.28] | 1 study · 358 participants | Very low Downgraded: risk of bias |
Ovulation Myo‐inositol vs antioxidant (melatonin) | no estimate extracted | NR | No studies |
Myo‐inositol compared to D‐chiro‐inositol as pre‐treatment to IVF in women with PCOS
Population: subfertile women with polycystic ovary syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Live birth Myo‐inositol vs D‐chiro‐inositol | no estimate extracted | NR | No studies |
Adverse event ‐ miscarriage Myo‐inositol vs D‐chiro‐inositol | OR 1.3 [0.27, 6.2] | 1 study · 84 participants | Very low Downgraded: risk of bias |
Adverse event ‐ multiple pregnancy Myo‐inositol vs D‐chiro‐inositol | no estimate extracted | NR | No studies |
Clinical pregnancy Myo‐inositol vs D‐chiro‐inositol | OR 3.86 [1.25, 11.89] | 1 study · 84 participants | Very low Downgraded: risk of bias |
Ovulation Myo‐inositol vs D‐chiro‐inositol | no estimate extracted | NR | No studies |
Myo‐inositol compared to an insulin‐sensitising agent (metformin) in women with PCOS undergoing ovulation induction
Population: subfertile women with polycystic ovary syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Live birth Myo‐inositol vs an insulin‐sensitising agent (metformin) | no estimate extracted | NR | No studies |
Adverse events Myo‐inositol vs an insulin‐sensitising agent (metformin) | no estimate extracted | NR | No studies |
Clinical pregnancy Myo‐inositol vs an insulin‐sensitising agent (metformin) | OR 1.91 [0.81, 4.49] | 1 study · 120 participants | Very low Downgraded: risk of bias |
Ovulation Myo‐inositol vs an insulin‐sensitising agent (metformin) | OR 1.86 [0.89, 3.87] | 1 study · 120 participants | Very low Downgraded: risk of bias |
Myo‐inositol compared to an ovulation induction agent (clomiphene) in women with PCOS undergoing ovulation induction
Population: subfertile women with polycystic ovary syndrome
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Live birth Myo‐inositol vs an ovulation induction agent (clomiphene) | OR 1.27 [0.48, 3.4] | 1 study · 75 participants | Very low Downgraded: risk of bias |
Adverse event ‐ miscarriage Myo‐inositol vs an ovulation induction agent (clomiphene) | no estimate extracted | NR | No studies |
Adverse event ‐ multiple pregnancy Myo‐inositol vs an ovulation induction agent (clomiphene) | OR 0.21 [0.01, 4.43] | 1 study · 75 participants | Very low Downgraded: risk of bias |
Clinical pregnancy Myo‐inositol vs an ovulation induction agent (clomiphene) | no estimate extracted | NR | No studies |
Ovulation rate Myo‐inositol vs an ovulation induction agent (clomiphene) | OR 0.59 [0.2, 1.68] | 1 study · 75 participants | Very low Downgraded: risk of bias |